首页|期刊导航|健康发展与政策研究|血清25-羟基维生素D用于中国65岁及以上人群骨折风险筛查的成本效用分析

血清25-羟基维生素D用于中国65岁及以上人群骨折风险筛查的成本效用分析OA

Cost-utility analysis of serum 25-hydroxyvitamin D for screening fracture risk in Chinese population aged 65 and above

中文摘要英文摘要

目的 评估中国65岁及以上老年人群进行血清25-羟基维生素D[25(OH)D]筛查的健康获益和经济价值.方法 建立决策树和马尔可夫模型,模拟在中国65岁及以上老年人群中"筛查"(筛查组)与"未筛查"(未筛查组)策略的健康获益与成本,除筛查组维生素D充足的老年人外,其他均基于意愿选择是否补充维生素D和钙.基于公开发表文献、公共数据库、专家访谈等方式获取研究基线、临床、成本与效用等关键参数.使用单因素和概率敏感性分析评估参数不确定性,并设置围绝经期女性、人口深度老龄化地区(四川省)及不同补充意愿3种情境进行分析.结果 在未筛查组中,25(OH)D缺乏人群选择补充维生素D和钙的意愿概率为25.00%;筛查组中,选择补充的概率提升至65.00%.与未筛查组相比,筛查组人均终身获得了0.014个增量质量调整生命年(quality-adjusted life year,QALY),总成本降低197.12元.单因素敏感性分析显示,无论参数在预设范围内如何变动,各策略的增量成本效用比(incremental costutility ratio,ICUR)均始终低于意愿支付阈值(95 749元/QALY).概率敏感性分析结果显示,筛查为绝对优势策略的概率达88.32%.在特定高风险人群(≥50岁围绝经期女性)、人口深度老龄化地区(四川省),以及在不同的患者补充意愿假设下,该策略的结果始终表现为成本节约(绝对优势)或具有很高的成本效用.结论 65岁及以上老年人群进行25(OH)D筛查可以降低骨折事件发生风险,提高健康获益,同时减轻经济负担,具有绝对优势.

Objective This study aims to evaluate the health benefits and economic value of serum 25(OH)D screening among adults aged 65 and above in China.Methods A decision tree and a Markov model were developed to simulate the health benefits and costs of the"screening"strategy(screening group)versus the"non-screening"strategy(non-screening group)in the Chinese population aged 65 years and older.In both strategies,supplementation of vitamin D and calcium was based on individual willingness,except for vitamin D-sufficient individuals identified in the screening group,who did not supplement.Key baseline,clinical,cost,and utility parameters were derived from published literature,public databases,and expert interviews.One-way and probabilistic sensitivity analyses were conducted to assess parameter uncertainty.3 scenario analyses performed,targeting perimenopausal women,a region with a severely aged population(Sichuan Province),and varying levels of supplementation willingness.Results In the non-screening group,the willingness to supplement vitamin D and calcium among 25(OH)D-deficient individuals was 25.00%;in the screening group,the willingness rose to 65.00%among the same deficient population.Compared with the non-screening group,the screening group gained 0.014 incremental QALYs per person and saved 197.12 CNY in total lifetime costs per person.One-way sensitivity analysis showed that the incremental cost-utility ratio(ICUR)consistently remained below the willingness-to-pay threshold(95 749 CNY/QALY)regardless of parameter variation.Probabilistic sensitivity analysis showed that the screening strategy was dominant in 88.32%of simulations.Across all three scenarios—high-risk perimenopausal women(≥50 years),a region with a severely aged population(Sichuan Province),and varying assumptions regarding patient willingness to supplement—the screening strategy consistently demonstrated either cost savings(dominance)or a favorable cost-utility profile.Conclusion 25(OH)D screening in adults aged 65 and above can reduce fracture risk,improve health outcomes,and alleviate economic burden,representing a dominant strategy.

刘玉萍;帅平;刘佑韧;左晨钰;吴柏纬;宣建伟

四川省医学科学院·四川省人民医院(电子科技大学附属医院)健康管理中心,四川 成都 610000四川省医学科学院·四川省人民医院(电子科技大学附属医院)健康管理中心,四川 成都 610000四川省医学科学院·四川省人民医院(电子科技大学附属医院)健康管理中心,四川 成都 610000中山大学药学院,广东 广州 510000中山大学药学院,广东 广州 510000中山大学药学院,广东 广州 510000

医药卫生

25(OH)D筛查维生素D老年人群成本效用骨折

25(OH)D screeningVitamin Delderly populationcost-utility analysisfracture

《健康发展与政策研究》 2026 (3)

413-423,11

10.12458/HDPR.202502002

评论